NCT05129462View on ClinicalTrials.gov

Consistency of PD-L1 Detecting Method Between E1L3N and 22C3 Monoclonal Antibodies in NSCLC Patients

CompletedOBSERVATIONAL
Enrollment

52

Participants

Timeline

Start Date

August 5, 2018

Primary Completion Date

September 5, 2021

Study Completion Date

October 1, 2021

Conditions
Non Small Cell Lung Cancer
Trial Locations (1)

410013

Hunan Cancer Hospital, Changsha

All Listed Sponsors
lead

Hunan Province Tumor Hospital

OTHER

NCT05129462 - Consistency of PD-L1 Detecting Method Between E1L3N and 22C3 Monoclonal Antibodies in NSCLC Patients | Biotech Hunter | Biotech Hunter